Peptide

Davunetide (NAP)

Also known as

NAP · NAPVSIPQ · davunetide peptide

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	NAP, an experimental eight-amino-acid peptide derived from ADNP, discussed for memory, brain fog and brain-cell protection.
Formulation	AL-108 was developed as a metered nasal formulation. Injectable research products do not inherit its trial results; this is not a Khavinson bioregulator.

Notes

Davunetide, also called NAP, is an experimental peptide discussed for memory, brain fog and protecting brain cells. Interest comes largely from its research story; clear self-use accounts are scarce. Nasal clinical formulations, injectable research products and neighboring nootropics should not be treated as interchangeable.

NAP names one eight-part peptide. NAPVSIPQ is the letter sequence of eight amino acids taken from a larger protein called ADNP. Research examines support for the cell's internal scaffolding, called microtubules. This is an experimental brain-protection idea, not proof of repaired memory. Gozes et al. 2024: Davunetide sex-dependent MCI reanalysis (Official context · Accessed 2026-09-30)

Nasal development is different from injectable products. AL-108 is the nasal development name. Online guides also discuss injections under the skin, but those products cannot inherit the results of a metered clinical nasal spray. Davunetide is not a Khavinson organ bioregulator. Morimoto et al. 2013: intranasal AL-108 in mild cognitive impairment (Official context · Accessed 2026-09-30) · Peptidings: NAP community dosing and combinations (Community guide · Accessed 2026-09-30)

Source context — Gozes et al. 2024: Davunetide sex-dependent MCI reanalysis: Publisher body opened via cookie-error redirected URL; direct cached ref was intermittently unavailable. Older-trial subgroup reanalysis, not a new confirmatory trial; excludes pregnancy population.

Source context — Morimoto et al. 2013: intranasal AL-108 in mild cognitive impairment: Abstract reviewed, not original full text. Disease population and exploratory signals cannot establish enhancement in healthy users.

Source context — Peptidings: NAP community dosing and combinations: Commercial secondary site; not firsthand. Some formal-trial summaries and reference IDs are misleading, so its efficacy/safety claims are not adopted.

What people notice

Community feeling	The inspected discussions supply interest and secondhand clarity claims, without a dependable direct Davunetide feeling or day-one outcome.
Human research	The mild cognitive impairment (MCI) trial missed its main memory outcome; the progressive supranuclear palsy (PSP) trial missed both main outcomes. Later subgroup findings are exploratory.

Notes

Clearer thinking and easier learning. A Biohackers poster asks about Davunetide while seeking short-term memory support and relief from stress-related brain fog. That is a reason for interest, not a report that Davunetide helped; their follow-up describes choosing magnesium instead. r/Biohackers: nootropics alongside Vyvanse (Community discussion · Accessed 2026-09-30)

No dependable description of the feeling. The detailed stimulant-co-use commenter explicitly had not tried Davunetide. Older mood and motivation notes are confounded by caffeine, sleep and other stimulants; they do not establish a Davunetide buzz, calmness or day-one benefit. r/Biohackers: nootropics alongside Vyvanse (Community discussion · Accessed 2026-09-30)

Subtle benefit and minimal effect are secondhand descriptions. The wiki claims mild clarity and uncertain results but does not link the individual reports. Its report count cannot establish consensus, and absence of documented adverse accounts is not a safety finding. Peptide Protocol Wiki: Davunetide community protocols (Community guide · Accessed 2026-09-30)

MCI: distinct nasal arms, with a negative main memory result. The 12-week study used 5 mg once daily or 15 mg per administration twice daily: 5 or 30 mg/day. Its main composite memory outcome was negative; individual-test and later subgroup signals remain exploratory. Morimoto et al. 2013: intranasal AL-108 in mild cognitive impairment (Official context · Accessed 2026-09-30) · Gozes et al. 2024: Davunetide sex-dependent MCI reanalysis (Official context · Accessed 2026-09-30)

PSP: 30 mg per nasal administration, twice daily. That is 60 mg/day for 52 weeks, not 30 mg/day. The 313-person study found no benefit on either main outcome for progressive supranuclear palsy, a serious neurological disease. Boxer et al. 2014: Davunetide in progressive supranuclear palsy (Official context · Accessed 2026-09-30)

Neuroprotection narrative and trial context: Community and regional literature frame NAP/ADNP benefits around neuroprotection and ‘normalization.’ In formal studies, intranasal davunetide was generally tolerated but missed the MCI composite cognitive endpoint and 52-week PSP primary endpoints; individual and post-hoc signals remain exploratory. [community] [trial]

Original trial abstract: 144 participants, 12 weeks; no statistically significant composite cognitive memory benefit, with individual-test signals. Morimoto et al. 2013: intranasal AL-108 in mild cognitive impairment (Official context · Accessed 2026-09-30)

Source context — r/Biohackers: nootropics alongside Vyvanse: Anonymous question and replies, not a Davunetide first-person log. Does not establish interaction safety or lack of benefit.

Source context — Peptide Protocol Wiki: Davunetide community protocols: Commercial secondary compilation with email/vendor promotion. Named reports cannot be checked from its citations; nasal daily-total prose conflicts with table frequency. Its claims are not counted as ten inspected people.

Source context — Boxer et al. 2014: Davunetide in progressive supranuclear palsy: Abstract reviewed; PSP disease trial is not a cognitive-enhancement experiment or subjective duration study.

Doses people talk about

Secondary community charts	A wiki calls nasal 2–5 mg a daily total but elsewhere lists it once or twice daily. Its injected 1–5 mg once-daily claim lacks a traceable personal log.
MCI trial context	Separate nasal arms used 5 mg once daily or 15 mg per administration twice daily: 5 or 30 mg/day for 12 weeks.
PSP trial context	30 mg per nasal administration twice daily, totaling 60 mg/day for 52 weeks. These are trial amounts, not a community regimen.

Notes

Nasal: 2–5 mg, with conflicting frequency wording. Peptide Protocol Wiki calls this a daily total, yet its table lists 2–5 mg one or two times daily. Those meanings conflict; neither establishes a checked user dose. Peptide Protocol Wiki: Davunetide community protocols (Community guide · Accessed 2026-09-30)

Under the skin: 1–5 mg once daily is a secondary claim. The same wiki lists it without a traceable individual log. Peptidings instead describes nasal 5–30 mg figures as extrapolations from trials. These are different claims, not a validated injection band or nasal-to-injection conversion. Peptide Protocol Wiki: Davunetide community protocols (Community guide · Accessed 2026-09-30) · Peptidings: NAP community dosing and combinations (Community guide · Accessed 2026-09-30)

Source context — Boxer et al. 2014: Davunetide in progressive supranuclear palsy: Abstract reviewed; PSP disease trial is not a cognitive-enhancement experiment or subjective duration study.

Half-life, onset & duration

Felt onset	Not established in the inspected accounts; timing for other nootropics does not supply a Davunetide onset.
Felt duration	No dependable human felt window. A dashboard's 12-hour active-duration claim lacks an accompanying Davunetide use log.
Half-life	No checked human value. A roughly 15-minute website claim lacks clear human grounding; the 70.7-minute nasal plasma result is from rats.

Notes

No established first-dose onset. The Biohackers replies give timing for other nootropics, not Davunetide. Biomogging's 0.5-hour peak is not demonstrated as the time a person first notices clearer thinking. r/Biohackers: nootropics alongside Vyvanse (Community discussion · Accessed 2026-09-30) · Biomogging Davunetide timing dashboard (Secondhand community claim · Accessed 2026-09-30)

The 12-hour dashboard claim is unverified. Biomogging displays this active-duration figure without an accompanying Davunetide experience log. Older hours-long nasal/nootropic comparisons also do not establish NAP's felt window or persistence after stopping. Biomogging Davunetide timing dashboard (Secondhand community claim · Accessed 2026-09-30)

A roughly 15-minute claim lacks clear human grounding. Biomogging repeats this plasma estimate without a checked human measurement attached to the number. It cannot define a human half-life, a dosing interval or how long memory effects last. Biomogging Davunetide timing dashboard (Secondhand community claim · Accessed 2026-09-30)

Rat timing is separate from human experience. The conference abstract reports nasal plasma half-life 70.7 ± 34.0 minutes; intravenous plasma 12.2 ± 0.208 minutes and brain-fluid half-life 9.34 ± 4.00 minutes. Nasal blood levels peaked around 19 minutes and brain-fluid levels at 20–30 minutes. These are anesthetized-rat measurements, not human onset or duration. Morimoto et al.: serial NAPVSIPQ plasma and CSF pharmacokinetics (Animal context · Accessed 2026-09-30)

Source context — r/Biohackers: nootropics alongside Vyvanse: Anonymous question and replies, not a Davunetide first-person log. Does not establish interaction safety or lack of benefit.

Source context — Biomogging Davunetide timing dashboard: Biohacking protocol compilation rather than measured user timing. Dashboard values lack a clear human route/population measurement; unsupported mechanistic certainties and dose ladder excluded.

Source context — Morimoto et al.: serial NAPVSIPQ plasma and CSF pharmacokinetics: Abstract and metadata only; full text unavailable. Page identifies January 2006 conference paper, unlike frozen title's 2014 label. Animal values never become human felt windows.

Cycles people discuss

Secondary schedules	Wiki tables describe 4–12 weeks nasal or 4–8 weeks injected, without traceable user logs or a validated break.
Older comparisons	10–20-day courses and seasonal repeats come from general bioregulator culture. They are not established Davunetide cycles.

Notes

Wiki tables: 4–12 weeks nasal; 4–8 weeks injected. These are secondary schedules without traceable user logs, not confirmed safe courses. Neither specifies a validated break. Peptide Protocol Wiki: Davunetide community protocols (Community guide · Accessed 2026-09-30)

10–20 days and seasonal repeats come from bioregulator culture. That older comparison does not establish a Davunetide cycle. Weeks-on/weeks-off discussion likewise supplies no universal off-period; trial follow-up is observation, not a recommended break.

Stacks

No checked combination	The saved accounts do not describe a direct Davunetide stack experience. Questions naming Semax, Selank, Noopept, Dihexa or Vyvanse do not demonstrate combined use.

Notes

Bioregulator marketing versus adjacent nootropics: Older organ-system protocols group multiple bioregulators, but Davunetide is not a Khavinson/cytomedine bioregulator. In the inspected discussion it appears beside Semax, Selank, Noopept and Dihexa in questions, without a first-person Davunetide stack account. [community]

A stack question is not an interaction check. Being mentioned alongside Vyvanse, Semax or Selank does not show that Davunetide combines safely with them. Sleep changes, caffeine and multiple compounds make mood or side-effect attribution difficult. r/Biohackers: nootropics alongside Vyvanse (Community discussion · Accessed 2026-09-30)

Source context — r/Biohackers: nootropics alongside Vyvanse: Anonymous question and replies, not a Davunetide first-person log. Does not establish interaction safety or lack of benefit.

Watch for

Nasal reactions	Nosebleeds, runny nose and nasal discomfort were more frequent than placebo in the PSP trial.
Product and safety gaps	Purity, allergy, formulation differences and long-term research-product safety remain uncertain. General injection reactions do not establish Davunetide-specific rates.
Unanswered interactions	Mention beside stimulants does not check interaction safety; trial results also do not establish pregnancy safety.

Notes

Nosebleeds, runny nose and nasal discomfort. These were more frequent with Davunetide than placebo in the PSP nasal trial. Broad claims of good tolerability should not erase those problems. Boxer et al. 2014: Davunetide in progressive supranuclear palsy (Official context · Accessed 2026-09-30)

Unknown products and uncertain long-term safety. Research-market purity, allergy and formulation differences remain concerns. Redness, itching, lumps and bruising are general injection cautions, not established Davunetide reaction rates. Storage depends on the actual formulation; a generic peptide rule cannot settle it.

Trial populations leave important gaps. The MCI trial excluded women of childbearing potential; it does not answer pregnancy safety. Severe allergy, chest pain, new neurological symptoms or uncontrolled blood pressure or glucose need medical care, not a forum explanation. Gozes et al. 2024: Davunetide sex-dependent MCI reanalysis (Official context · Accessed 2026-09-30)

Source context — Boxer et al. 2014: Davunetide in progressive supranuclear palsy: Abstract reviewed; PSP disease trial is not a cognitive-enhancement experiment or subjective duration study.

Source context — r/Biohackers: nootropics alongside Vyvanse: Anonymous question and replies, not a Davunetide first-person log. Does not establish interaction safety or lack of benefit.

Full notes

What Davunetide actually is

NAP names one eight-part peptide. NAPVSIPQ is the letter sequence of eight amino acids taken from a larger protein called ADNP. Research examines support for the cell's internal scaffolding, called microtubules. This is an experimental brain-protection idea, not proof of repaired memory. Official context
Nasal development is different from injectable products. AL-108 is the nasal development name. Online guides also discuss injections under the skin, but those products cannot inherit the results of a metered clinical nasal spray. Davunetide is not a Khavinson organ bioregulator. Official context Community guide Community

What people hope to gain

Clearer thinking and easier learning. A Biohackers poster asks about Davunetide while seeking short-term memory support and relief from stress-related brain fog. That is a reason for interest, not a report that Davunetide helped; their follow-up describes choosing magnesium instead. Reddit
Memory protection and less anxiety. Biohacking writer Rake sees promise in a reanalysis separating men's and women's memory results. The writer acknowledges small subgroups and analysis after the trial. This does not establish a sex-based self-use dose or a reliable calming effect. Substack / personal biohacking blog
No dependable description of the feeling. The detailed stimulant-co-use commenter explicitly had not tried Davunetide. Older mood and motivation notes are confounded by caffeine, sleep and other stimulants; they do not establish a Davunetide buzz, calmness or day-one benefit. Reddit Community

Doses circulated online

Nasal: 2–5 mg, with conflicting frequency wording. Peptide Protocol Wiki calls this a daily total, yet its table lists 2–5 mg one or two times daily. Those meanings conflict; neither establishes a checked user dose. Community guide
Under the skin: 1–5 mg once daily is a secondary claim. The same wiki lists it without a traceable individual log. Peptidings instead describes nasal 5–30 mg figures as extrapolations from trials. These are different claims, not a validated injection band or nasal-to-injection conversion. Community guide Community guide

Half-life: what the numbers mean

A roughly 15-minute claim lacks clear human grounding. Biomogging repeats this plasma estimate without a checked human measurement attached to the number. It cannot define a human half-life, a dosing interval or how long memory effects last. Biomogging

When an effect might start

No established first-dose onset. The Biohackers replies give timing for other nootropics, not Davunetide. Biomogging's 0.5-hour peak is not demonstrated as the time a person first notices clearer thinking. Reddit Biomogging

How long a noticeable effect lasts

The 12-hour dashboard claim is unverified. Biomogging displays this active-duration figure without an accompanying Davunetide experience log. Older hours-long nasal/nootropic comparisons also do not establish NAP's felt window or persistence after stopping. Biomogging Community

Courses and breaks

Wiki tables: 4–12 weeks nasal; 4–8 weeks injected. These are secondary schedules without traceable user logs, not confirmed safe courses. Neither specifies a validated break. Community guide
10–20 days and seasonal repeats come from bioregulator culture. That older comparison does not establish a Davunetide cycle. Weeks-on/weeks-off discussion likewise supplies no universal off-period; trial follow-up is observation, not a recommended break. Community

Cautions that matter

Nosebleeds, runny nose and nasal discomfort. These were more frequent with Davunetide than placebo in the PSP nasal trial. Broad claims of good tolerability should not erase those problems. Official context
Unknown products and uncertain long-term safety. Research-market purity, allergy and formulation differences remain concerns. Redness, itching, lumps and bruising are general injection cautions, not established Davunetide reaction rates. Storage depends on the actual formulation; a generic peptide rule cannot settle it. Community
A stack question is not an interaction check. Being mentioned alongside Vyvanse, Semax or Selank does not show that Davunetide combines safely with them. Sleep changes, caffeine and multiple compounds make mood or side-effect attribution difficult. Reddit Community Community
Trial populations leave important gaps. The MCI trial excluded women of childbearing potential; it does not answer pregnancy safety. Severe allergy, chest pain, new neurological symptoms or uncontrolled blood pressure or glucose need medical care, not a forum explanation. Official context Community

Human trials and animal timing

MCI: distinct nasal arms, with a negative main memory result. The 12-week study used 5 mg once daily or 15 mg per administration twice daily: 5 or 30 mg/day. Its main composite memory outcome was negative; individual-test and later subgroup signals remain exploratory. Official context Official context
PSP: 30 mg per nasal administration, twice daily. That is 60 mg/day for 52 weeks, not 30 mg/day. The 313-person study found no benefit on either main outcome for progressive supranuclear palsy, a serious neurological disease. Official context
Rat timing is separate from human experience. The conference abstract reports nasal plasma half-life 70.7 ± 34.0 minutes; intravenous plasma 12.2 ± 0.208 minutes and brain-fluid half-life 9.34 ± 4.00 minutes. Nasal blood levels peaked around 19 minutes and brain-fluid levels at 20–30 minutes. These are anesthetized-rat measurements, not human onset or duration. Animal context

From community discussion

Protecting cells is not the same as pruning connections. A Nootropics commenter guesses that Davunetide might be the peptide involved in removing unwanted brain connections; the original poster doubts that identity. The exchange supplies no verified pruning benefit or Davunetide–Dihexa stack. Reddit
Early interest preceded clear use accounts. In 2013, a LongeCity member was curious about NAP after reading preclinical protection claims. Nearby dramatic experiences concern Dihexa. Curiosity and quoted laboratory results are different from someone reporting what NAP did. LongeCity
Subtle benefit and minimal effect are secondhand descriptions. The wiki claims mild clarity and uncertain results but does not link the individual reports. Its report count cannot establish consensus, and absence of documented adverse accounts is not a safety finding. Community guide